The untapped potential of Gallium 68-PET: The next wave of 68Ga-agents

68Gallium-PET (68Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a 68Ge/68Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of 68Ga permits imaging applications with sufficient radioactivity while maintaining patient dose to an acceptable level. Furthermore, due to superior resolution, 68Ga-PET agents have the ability to replace current SPECT agents in many applications. This article outlines the upcoming agents and challenges faced during the translational development of 68Ga agents.

► Novel preclinical probes for 68Ga PET are reviewed.
► Pretargeting strategies for Ga68 imaging are discussed.
► The importance of specific activity in development of 68Ga-probes is discussed.